evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,534 questions · 5,247 findings · 456 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,142 · 21.8%GRADE not reported 1,503 · 28.6%Very low 1,040 · 19.8%Low 869 · 16.6%Moderate 554 · 10.6%High 139 · 2.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Perampanel add‐on vs placebo

Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on vs placebo

Proportion of participants who experienced ≥ 1 adverse effect · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on leads to higher proportion of participants who experienced ≥ 1 adverse effect compared with placebo (high certainty).

1 finding from 1 review

Perampanel add‐on vs placebo

Proportion of participants who experienced ataxia · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher proportion of participants who experienced ataxia compared with placebo (low certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Survival · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: total score · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: relative change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Time to first pulmonary exacerbation · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review